Bardy Diagnostics
Bardy Diagnostics develops ambulatory ECG monitoring solutions, including the Carnation Ambulatory Monitor (CAM) Patch, which is a lightweight, extended-wear cardiac patch monitor designed to optimize P-wave signal capture for more accurate arrhythmia detection. Its products are used by healthcare professionals to obtain clear and actionable cardiac event data for patient diagnosis and management. The organization aims to improve the quality and accuracy of ambulatory cardiac monitoring to support better patient outcomes.
Facts
- HQ
- Seattle
- Sectors
- Medical devices, Healthcare technology, Cardiology diagnostic devices, Patient monitoring
- Founded
- 2013
- Type
- Corporation Seattle business license
- Registered name
- Bardy Diagnostics Inc Seattle business license
- Stage
- former-startup
- Members see funding amounts. .
- Founders
- Gust H. Bardy, M.D.
Is this your organization? Claim it
Bardy Diagnostics Reveals $375M Total Funding; $36M Series B Recorded in April 2019
Bardy Diagnostics, headquartered in New Providence, NJ, has disclosed $375M in total funding, with its latest recorded round a $36M Series B in April 2019. The company’s leadership links to Baxter International via Andrew Hider, and investors include River Cities Capital Funds, HealthQuest Capital, Aperture Venture Partners, and others.
Hillrom to complete $367M acquisition of Bardy Diagnostics after Delaware judge orders deal to proceed
Hillrom will proceed with its previously announced $367 million acquisition of Seattle startup Bardy Diagnostics after a Delaware judge ordered the deal to close following a dispute over sharp Medicare reimbursement cuts that briefly led Hillrom to try to withdraw.
Hillrom to Buy Bardy Diagnostics for $375 Million, Adding CAM Wearable ECG Patch and P‑Wave Signal Technology
Hillrom will acquire Bardy Diagnostics for $375 million in cash plus potential milestone payments, adding BardyDx’s CAM wearable cardiac-monitoring patch and its P-wave–focused signal-processing tech to Hillrom’s cardiology portfolio; BardyDx reports $30 million annualized revenue, over $20 million net operating losses, and about 230 employees. The deal is expected to close in Hillrom’s fiscal Q2 2021, subject to customary closing conditions.
See all 10 stories, episodes and videos about Bardy Diagnostics.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
Gust Bardy Founder